We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Seeking Clues to Medtronic (MDT) Q1 Earnings? A Peek Into Wall Street Projections for Key Metrics
Read MoreHide Full Article
In its upcoming report, Medtronic (MDT - Free Report) is predicted by Wall Street analysts to post quarterly earnings of $1.20 per share, reflecting no change compared to the same period last year. Revenues are forecasted to be $7.9 billion, representing a year-over-year increase of 2.5%.
Over the past 30 days, the consensus EPS estimate for the quarter has remained unchanged. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.
Before a company reveals its earnings, it is vital to take into account any changes in earnings projections. These revisions play a pivotal role in predicting the possible reactions of investors toward the stock. Multiple empirical studies have consistently shown a strong association between trends in earnings estimates and the short-term price movements of a stock.
While investors typically rely on consensus earnings and revenue estimates to gauge how the business may have fared during the quarter, examining analysts' projections for some of the company's key metrics often helps gain a deeper insight.
In light of this perspective, let's dive into the average estimates of certain Medtronic metrics that are commonly tracked and forecasted by Wall Street analysts.
According to the collective judgment of analysts, 'Net Sales- World Wide Revenue- Cardiovascular' should come in at $2.92 billion. The estimate suggests a change of +2.6% year over year.
Analysts predict that the 'Net Sales- World Wide Revenue- Diabetes' will reach $613.04 million. The estimate suggests a change of +6.1% year over year.
The collective assessment of analysts points to an estimated 'Net Sales- World Wide Revenue- Medical Surgical' of $2.06 billion. The estimate suggests a change of +1.1% year over year.
Based on the collective assessment of analysts, 'Net Sales- World Wide Revenue- Neuroscience' should arrive at $2.29 billion. The estimate indicates a change of +3.3% from the prior-year quarter.
Analysts' assessment points toward 'Net Sales- U.S. Revenue' reaching $4.03 billion. The estimate points to a change of +2.6% from the year-ago quarter.
Analysts expect 'Net Sales- ROW- Cardiovascular- Structural Heart & Aortic' to come in at $480.82 million. The estimate points to a change of +5.2% from the year-ago quarter.
The average prediction of analysts places 'Net Sales- ROW- Neuroscience- Cranial & Spinal Technologies' at $292.45 million. The estimate indicates a year-over-year change of +3.7%.
The consensus among analysts is that 'Net Sales- ROW- Neuroscience- Specialty Therapies' will reach $307.36 million. The estimate suggests a change of +1.4% year over year.
It is projected by analysts that the 'Net Sales- ROW- Cardiovascular' will reach $1.55 billion. The estimate indicates a year-over-year change of +3.6%.
The combined assessment of analysts suggests that 'Net Sales- ROW- Cardiovascular- Coronary & Peripheral Vascular' will likely reach $325.95 million. The estimate suggests a change of +3.2% year over year.
The consensus estimate for 'Net Sales- U.S. Revenue- Cardiovascular- Cardiac Rhythm & Heart Failure' stands at $734.17 million. The estimate indicates a change of +2% from the prior-year quarter.
Analysts forecast 'Net Sales- U.S. Revenue- Cardiovascular' to reach $1.37 billion. The estimate points to a change of +1.5% from the year-ago quarter.
Over the past month, shares of Medtronic have returned +0.6% versus the Zacks S&P 500 composite's -2.9% change. Currently, MDT carries a Zacks Rank #4 (Sell), suggesting that it may underperform the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Seeking Clues to Medtronic (MDT) Q1 Earnings? A Peek Into Wall Street Projections for Key Metrics
In its upcoming report, Medtronic (MDT - Free Report) is predicted by Wall Street analysts to post quarterly earnings of $1.20 per share, reflecting no change compared to the same period last year. Revenues are forecasted to be $7.9 billion, representing a year-over-year increase of 2.5%.
Over the past 30 days, the consensus EPS estimate for the quarter has remained unchanged. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.
Before a company reveals its earnings, it is vital to take into account any changes in earnings projections. These revisions play a pivotal role in predicting the possible reactions of investors toward the stock. Multiple empirical studies have consistently shown a strong association between trends in earnings estimates and the short-term price movements of a stock.
While investors typically rely on consensus earnings and revenue estimates to gauge how the business may have fared during the quarter, examining analysts' projections for some of the company's key metrics often helps gain a deeper insight.
In light of this perspective, let's dive into the average estimates of certain Medtronic metrics that are commonly tracked and forecasted by Wall Street analysts.
According to the collective judgment of analysts, 'Net Sales- World Wide Revenue- Cardiovascular' should come in at $2.92 billion. The estimate suggests a change of +2.6% year over year.
Analysts predict that the 'Net Sales- World Wide Revenue- Diabetes' will reach $613.04 million. The estimate suggests a change of +6.1% year over year.
The collective assessment of analysts points to an estimated 'Net Sales- World Wide Revenue- Medical Surgical' of $2.06 billion. The estimate suggests a change of +1.1% year over year.
Based on the collective assessment of analysts, 'Net Sales- World Wide Revenue- Neuroscience' should arrive at $2.29 billion. The estimate indicates a change of +3.3% from the prior-year quarter.
Analysts' assessment points toward 'Net Sales- U.S. Revenue' reaching $4.03 billion. The estimate points to a change of +2.6% from the year-ago quarter.
Analysts expect 'Net Sales- ROW- Cardiovascular- Structural Heart & Aortic' to come in at $480.82 million. The estimate points to a change of +5.2% from the year-ago quarter.
The average prediction of analysts places 'Net Sales- ROW- Neuroscience- Cranial & Spinal Technologies' at $292.45 million. The estimate indicates a year-over-year change of +3.7%.
The consensus among analysts is that 'Net Sales- ROW- Neuroscience- Specialty Therapies' will reach $307.36 million. The estimate suggests a change of +1.4% year over year.
It is projected by analysts that the 'Net Sales- ROW- Cardiovascular' will reach $1.55 billion. The estimate indicates a year-over-year change of +3.6%.
The combined assessment of analysts suggests that 'Net Sales- ROW- Cardiovascular- Coronary & Peripheral Vascular' will likely reach $325.95 million. The estimate suggests a change of +3.2% year over year.
The consensus estimate for 'Net Sales- U.S. Revenue- Cardiovascular- Cardiac Rhythm & Heart Failure' stands at $734.17 million. The estimate indicates a change of +2% from the prior-year quarter.
Analysts forecast 'Net Sales- U.S. Revenue- Cardiovascular' to reach $1.37 billion. The estimate points to a change of +1.5% from the year-ago quarter.
View all Key Company Metrics for Medtronic here>>>
Over the past month, shares of Medtronic have returned +0.6% versus the Zacks S&P 500 composite's -2.9% change. Currently, MDT carries a Zacks Rank #4 (Sell), suggesting that it may underperform the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>